公开(公告)号：US20240335518A1

公开(公告)日：2024-10-10

申请号：US18505870

申请日：2023-11-09

申请人： Quadram Institute Bioscience

发明人： Regis Stentz ,  Simon Carding

IPC分类号： A61K39/112 ,  A61K39/00 ,  A61K39/02 ,  A61P37/04 ,  C12N15/74

CPC分类号： A61K39/0275 ,  A61K39/0291 ,  A61P37/04 ,  C12N15/74 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/55594 ,  A61K2039/575

摘要： The present invention relates to a vaccine suitable for immunisation against influenza, plague or Y. pestis infection said vaccine comprising outer membrane vesicles (OMVs) and the plague vaccine including the V and/or F1 antigens of Y. pestis.

公开(公告)号：US20240293539A1

公开(公告)日：2024-09-05

申请号：US18282143

申请日：2022-03-14

申请人： ICOSAGEN CELL FACTORY OÜ

发明人： Mario PLAAS ,  Karin KOGERMANN ,  Eva ZUSINAITE ,  Toomas TIIRATS ,  Birgit AASMÄE ,  Ants KAVAK ,  Väinö POIKALAINEN ,  Lembit LEPASALU ,  Sander PIISKOP ,  Siimu ROM ,  Ruth OLTJER ,  Kadri KANGRO ,  Eve SANKOVSKI ,  Joachim GERHOLD ,  Anu PLANKEN ,  Raini PERT ,  Andres MÄNNIK ,  Andres TOVER ,  Mihhail KURASIN ,  Mart USTAV ,  Mart USTAV, Jr. ,  Kiira GILDEMANN

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K39/00 ,  A61K39/42 ,  A61P37/04

CPC分类号： A61K39/39508 ,  A61K9/0043 ,  A61K39/42 ,  A61P37/04 ,  A61K2039/505 ,  A61K2039/543 ,  A61K2039/552

摘要： A method to produce immunoglobulin preparations against viral infection in humans spreading via respiratory route is provided. The method comprises the steps of immunizing dairy cows during a third trimester of at least a first gestation period with antigen proteins derived from at least one virus strain, collecting hyperimmune bovine colostrum comprising immunoglobulins effective against the antigen protein of various strains of the virus, preparing whey from the colostrum, isolating the immunoglobulin molecules from the whey, and preparing an immunoglobulin preparation for use as an intranasal treatment. One aspect of the invention is to produce SARS-CoV-2 spike protein specific hyperimmune bovine colostrum comprising a high concentration of anti-SARS-CoV-2 antibodies. An intranasal delivery system for diminishing risk of SARS-CoV-2 infections in humans is provided.

公开(公告)号：US20240293532A1

公开(公告)日：2024-09-05

申请号：US18271901

申请日：2022-01-14

申请人： The U.S.A., as Represented by The Secretary, Department of Health and Human Services

发明人： Mark Connors

IPC分类号： A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61P31/14 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61K9/0043 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/545 ,  C12N2750/14121 ,  C12N2750/14122 ,  C12N2750/14134

摘要： A replication-competent adenovirus type 4 (Ad4) modified to express the SARS-COV-2 spike protein is described. The genome of the recombinant Ad4 is modified to have a deletion of at least a portion of the adenovirus E3 region to accommodate insertion of the spike protein coding sequence. Administration of the recombinant Ad4 to the upper respiratory tract elicits mucosal immunity, which is important for protection against SARS-COV-2 infection and for preventing transmission of the virus.

公开(公告)号：US20240252616A1

公开(公告)日：2024-08-01

申请号：US18016137

申请日：2021-07-16

申请人： GRIFFITH UNIVERSITY ,  INDIAN IMMUNOLOGICALS LIMITED

发明人： Surendran Mahalingam ,  Andres Merits ,  Xiang Liu

IPC分类号： A61K39/215 ,  A61K39/00 ,  A61P37/04 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61P37/04 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/543 ,  C12N2770/20034 ,  C12N2770/20062

摘要： This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-COV-2 comprising a partly codon deoptimized viral genome, SARS-COV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.

公开(公告)号：US12042536B2

公开(公告)日：2024-07-23

申请号：US18099035

申请日：2023-01-19

申请人： The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

发明人： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61P31/14 ,  A61P37/04 ,  C01F11/02 ,  C07D323/00 ,  C07K14/005 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K39/39 ,  A61P31/14 ,  A61P37/04 ,  C01F11/02 ,  C07D323/00 ,  C07K14/005 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55588 ,  C12N2770/24234

摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20240226276A1

公开(公告)日：2024-07-11

申请号：US18517578

申请日：2023-11-22

申请人： University of Maryland, College Park

发明人： Xiaoping ZHU ,  Weizhong LI ,  Tao WANG

IPC分类号： A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61K9/0043 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/543 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071

摘要： Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-CoV-2 or at risk of being exposed to SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.

公开(公告)号：US11980661B2

公开(公告)日：2024-05-14

申请号：US17558852

申请日：2021-12-22

申请人： FluGen, Inc.

发明人： Pamuk Bilsel ,  Yasuko Hatta

IPC分类号： A61K39/145 ,  A61K35/76 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/145 ,  A61K35/76 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/58 ,  A61K2039/70 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16162 ,  C12N2760/16171 ,  C12N2760/16234 ,  C12N2760/16262

摘要： Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.

公开(公告)号：US20240058430A1

公开(公告)日：2024-02-22

申请号：US17818548

申请日：2022-08-09

申请人： GEG TECH

发明人： Nicolas GRANDCHAMP

IPC分类号： A61K39/00

CPC分类号： A61K39/0005 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545

摘要： A method of vaccinating a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5′ to 3′: an RNA Booster sequence that includes or is the following ribonucleic acid sequence mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest encoding at least one antigen.

公开(公告)号：US11827693B2

公开(公告)日：2023-11-28

申请号：US14769795

申请日：2014-03-14

申请人： CONTRAFECT CORPORATION

发明人： Michael Wittekind ,  Adam Vigil

IPC分类号： C07K16/10 ,  A61K9/00 ,  A61K39/42 ,  A61K45/06 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K9/007 ,  A61K9/0043 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/543 ,  A61K2039/544 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76

摘要： The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.

公开(公告)号：US11759517B2

公开(公告)日：2023-09-19

申请号：US17689581

申请日：2022-03-08

申请人： CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA

发明人： Julio César Aguilar Rubido ,  Yadira Lobaina Mato ,  Enrique Iglesias Perez ,  Eduardo Pentón Arias ,  Gerardo Enrique Guillén Nieto ,  Jorge Agustin Aguiar Santiago ,  Sonia Gonzalez Blanco ,  Jorge Valdes Hernandez ,  Mariela Vazquez Catillo

IPC分类号： A61K39/39 ,  A61P31/20 ,  A61K39/29 ,  A61K39/00

CPC分类号： A61K39/292 ,  A61K39/39 ,  A61P31/20 ,  A61K2039/5258 ,  A61K2039/543 ,  A61K2039/555 ,  A61K2039/575

摘要： This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.